Sunshine vitamin: FANCL data reveals Vitamin D is most popular supplement during
ACI expects healthcare antiseptic manufacturers to lose most active ingredients
The US Food and Drug Administration (FDA) will ban some 80% of active ingredients currently allowed for use in healthcare antiseptics, the American Cleaning Institute (ACI) expects.
Plans to require manufacturers to submit data demonstrating the safety and efficacy of their antibacterial ingredients were set out in a 2015 proposed rule - and are expected to become law when the final rule is issued. The FDA will assess data submitted by industry and decide whether to classify actives as "generally recognised as safe and effective" (Gras/Grae), or ban their use in the products.
ACI expects triclosan to face a ban in healthcare products as well, along with more than 20 other ingredients, its associate vice president for environmental safety, Paul DeLeo, told CW+BiocidesHub.
Some substances will be banned due to a lack of support by industry, he said. "Companies know it won't get FDA approval so they are not willing to do the additional testing the agency is requiring."
Others will fail because the data to support them is too challenging to generate. The agency, he says, is asking for "new methods that we are not aware of anyone having successfully completed in this space", but it has been willing to give companies more time.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
2026-07-02
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Eastman Tritan Products for FANCL Cosmetics Packaging
-
Japanese brewer Kirin plans to acquire Fancl for $1.4 billion
-
Can Addressing Vitamin D Deficiency, Depression, and Diabetes Reduce the Risk of Young-Onset Dementia?
-
Pfizer's paxlovid reduces the risk of COVID-19 by 26%
-
The battle between Pfizer and Gilead over COVID-19 drugs will continue
-
1200 cases were newly prescribed by Junshi Biologic for mild to moderate disease
-
Twenty-five COVID-19 Vaccines In China Enter Stages Of Clinical Trials
-
Pfizer to Increase Production Capacity of COVID-19 Oral Drugs, Invest 120 Million US Dollars
-
Anke Bio and Afana Collaborate on mRNA Vaccines for Mutant Strains Such as COVID-19 Omicron
-
As Low as $25/session! Pfizer's COVID-19 Oral Drug Paxlovid Generic Drug Price Released
Recommend Reading
-
End of an Era: KDC/One to Close 150-Year-Old Somerset Cosmetics Factory as Production Shifts to Scotland
-
KKR Acquires Korean Cosmetics Packaging Firm Samhwa for $577 Million, Tripling TPG’s Return
-
Eigenmann & Veronelli to Distribute Evolved by Nature Bioactive Peptides in Italy, Spain and Portugal
-
DKSH Upgrades its Malaysia Innovation Center to Strengthen Technical Service Capabilities for the Southeast Asian Market
-
IFF to Establish Scent Creative Center in Mumbai
-
Bridgestone Sells Mexican Carbon Black Plant to Cabot for $70 Million Global Supply Chain Strategy Takes Major Step
-
China Shenhua Plans Major Asset Injection with 13 Companies Involved Stock Trading Halted for Up to 10 Days
-
BASF and BardeFu Sign Strategic Deal for 500000 Tons Acrylic Ester Supply Zhanjiang Megasite Faces Low Margins Amid China Glut
-
1 Million Ton Green Methanol Project Signed in Fujian with 15 Billion Yuan Investment Global Partners Set Sights on Clean Energy Chain
-
DuPont Q2 Net Sales Hit $3.3 Billion with 35 Percent Profit Jump Electronics Division Set for $9 Billion Value Boost